The company we interviewed for this episode, Frequency Therapeutics, is the subject of the most active thread on the Tinnitus Talk forum, with nearly 1 million views. So of course, we wanted to hear from directly!
Frequency Therapeutics is working on a new hearing regeneration treatment. Preliminary results suggest the drug might work particularly well to improve speech intelligibility, something which traditional hearing aids have not been able to achieve.
We spoke with Carl LeBel, PhD, the company’s Chief Development Officer, about how the drug was discovered, whether it might benefit tinnitus, and why speech intelligibility should be the primary measure of hearing. We also touch on the burning question of when FX-322 might hit the market.
Visit our patient community at https://www.tinnitustalk.com